medigraphic.com
Anales de la Sociedad Mexicana de Oftalmología y Archivos de la Asociación Para Evitar la Ceguera en México

2018, Number 3

<< Back Next >>

Rev Mex Oftalmol 2018; 92 (3)

Synergistic effect of combined IFN-alpha2b and IFN-gamma treatment for periocular basal cell carcinoma

Negrín-Caceres Y, Cabrera-Romero AC, Cárdenas-Monzón L, Ferrer-Pérez A, Batista-Hernández NE

Language: Spanish
References: 39
Page: 136-143
PDF size: 486.73 Kb.


ABSTRACT

Purpose: To evaluate the results for the application of the perilesional HerberPAG on periocular basal cell carcinoma. Methods: An experimental investigation was carried out on a group of 7 patients who were given the same treatment regimen with HeberPAG® 10.5 × 106 UI 3 times a week for 3 consecutive weeks. Demographic variables where considered as well as time of evolution, initial injury size, clinical subtype, histological subtype, clinical response, objective response and adverse effects. Results: The average time of evolution of the injury was 7.0 ± 1.6 months, with a higher diameter medium of 17.4 ± 2.3 mm. The clinic nodule-ulcerative subtype was presented on 42.9% of the subjects and the solid and superficial hostiological subtypes were presented with an equal proportion of 42.9%. Conclusions: The use of HerberPAG was effective and could be considered as a useful and a safe alternative as a conservative treatment in subjects with periocular basal cell carcinoma when other therapies are not available.


REFERENCES

  1. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep. 2015;7:53.

  2. Karimkhani C, Boyers LN, Dellavalle RP, Weinstock MA. It’s time for ‘keratinocyte carcinoma’ to replace the term ‘nonmelanoma skin cancer’. J Am Acad Dermatol. 2015;72:186-7.

  3. Mohan SV, Chang AL. Advanced Basal Cell Carcinoma: Epidemiology and Therapeutic Innovations. Curr Dermatol Rep. 2014;3:40-5.

  4. Baxter JM, Patel AN, Varma S. Facial basal cell carcinoma. BMJ. 2012;345:e5342.

  5. García Martín E, Fernández Tirado FJ. Periocular basal cell carcinoma treatment tendencies. Arch Soc Esp Oftalmol. 2010;85:261-2.

  6. Wang CJ, Zhang HN, Wu H. Clinicopathologic features and prognostic factors of malignant eyelid tumors. Int J Ophthalmol. 2013;6(4):442-7.

  7. Kale SM, Patil SB, Khare N. Clinicopathological analysis of eyelid malignancies - A review of 85 cases. Indian J Plast Surg. 2012;45(1):22-8.

  8. Marzuka AG, Book SE. Basal Cell Carcinoma: Pathogenesis, Epidemiology, Clinical Features, Diagnosis, Histopathology, and Management. Yale J Biol Med. 2015;88(2):167-79.

  9. Gulleth Y, Goldberg N, Silverman RP, Gastman BR. What is the best surgical margin for a Basal cell carcinoma: a meta-analysis of the literature. Plast Reconstr Surg. 2010;126(4):1222-31.

  10. Prokosch V, Thanos S, Spaniol K, Stupp T. Long-term outcome after treatment with 5% topical imiquimod cream in patients with basal cell carcinoma of the eyelids. Graefes Arch Clin Exp Ophthalmol. 2011;249:121-5.

  11. Fantini F, Greco A, Del Giovane C, Cesinaro AM, Venturini M, Zane C., et al. Photodynamic therapy for basal cell carcinoma: clinical and pathological determinants of response. J Eur Acad Dermatol Venereol. 2011;25(8):896-901.

  12. Cosgarea R, Susan M, Crisan M, Senila S. Photodynamic therapy using topical 5-aminolaevulinic acid vs. surgery for basal cell carcinoma. J Eur Acad Dermatol Venereol. 2013;27(8):980-4.

  13. Arits AH, Mosterd K, Essers BA, Spoorenberg E, Sommer A, De Rooij MJ, et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol. 2013;14(7):647-54.

  14. Smith V, Walton S. Treatment of facial basal cell carcinoma: A review. Hindawi Publishing Corporation. J Skin Can. 2011;2011:380371.

  15. Lasudry J. Management of eyelid tumors: general considerations. J Fr Ophtalmol. 2011;34(10):741-54.

  16. Good LM, Miller MD, High WA. Intralesional agents in the management of cutaneous malignancy: a review. J Am Acad Dermatol. 2011; 64(2):413-22.

  17. Garcia-Vega Y, Anasagasti-Angulo L, Valenzuela-Silva C, Navarro-Mestre M, Maribeth-Ordoñez S, Acosta-Medina D, et al. Retrospective Study of Periocular Non Melanoma Skin Cancer Treated with the Combination of IFN alpha2b and Gamma (HeberPAG®). J Clin Exp Ophthalmol. 2015;6:478.

  18. Jiménez Barbán Y, Vega Pupo C, Vila Pinillo D, Fernández Ychaso G, Arias Núñez V, Bello Rivero I. Uso de HeberPAG® en carcinoma basocelular periocular. Rev Cubana Oftalmol. 2014;27:3.

  19. Bello-Rivero I, Garcia-Vega Y, Valenzuela-Silva C. Development of a new formulation of interferons (HEBERPAG®) for BCC treatment. J Cancer Res Ther. 2013;1(10):235-243.

  20. Anasagasti Angulo L, Garcia Vega Y, Barcelona Perez S, Lopez Saura P, Bello Rivero I. Treatment of advanced, recurrent, resistant to previous treatments basal and squamous cell skin carcinomas with a synergistic formulation of interferons. Open, prospective study. BMC Cancer. 2009;9:262-74.

  21. García Vega Y, García García I, Collazo Caballero SE, Santely- Pravia EE, Cruz-Ramírez A, Tuero-Iglesias AD, et al. Pharmacokinetic and pharmacodynamic characterization of a new formulation containing synergistic proportions of interferons alpha-2b and gamma (HeberPAG®) in patients with mycosis fungoides: an open-label trial. BMC Pharmacol Toxicol. 2012;13:20.

  22. Rene C. Oculoplastic aspects of ocular oncology. Eye. 2013;27:199-207.

  23. Hayano SM, Whipple KM, Korn BS, Kikkawa DO. Principles of Periocular Reconstruction following Excision of Cutaneous Malignancy. J Skin Cancer. 2012;2012:438502.

  24. Lewin JM, Carucci JA. Advances in the management of basal cell carcinoma. F1000Prime Rep. 2015;7:53.

  25. Wu TP, Stein JA. Nonmelanoma skin cancer in young women. J Drugs Dermatol. 2013;12:568-72.

  26. Göppner D, Leverkus M. Basal Cell Carcinoma: From the Molecular Understanding of the Pathogenesis to Targeted Therapy of Progressive Disease. J Skin Cancer. 2011;2011:650258.

  27. Wehner MR, Shive ML, Chren MM, Han J, Qureshi AA, Linos E. Indoor tanning and non-melanoma skin cancer: systematic review and meta- analysis. BMJ. 2012;345:e5909.

  28. Ferrucci LM, Cartmel B, Molinaro AM, Leffell DJ, Bale AE, Mayne ST. Indoor tanning and risk of early-onset basal cell carcinoma. J Am Acad Dermatol. 2012;67(4):552-62.

  29. Robinson SN, Zens MS, Perry AE, Spencer SK, Duell EJ, Karagas MR. Photosensitizing agents and the risk of non-melanoma skin cancer: a population-based case-control study. J Invest Dermatol. 2013; 133(8):1950-5.

  30. Stern RS. PUVA Follow-Up Study. The risk of squamous cell and basal cell cancer associated with psoralen and ultraviolet A therapy: a 30-year prospective study. J Am Acad Dermatol. 2012;66(4):553-62.

  31. Danial C, Lingala B, Balise R, Oro AE, Reddy S, Colevas A, et al. Markedly improved overall survival in 10 consecutive patients with metastatic basal cell carcinoma. Br J Dermatol. 2013;169:673-6.

  32. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med. 2009;361: 1164-72.

  33. Sekulic A, Migden MR, Oro AE, Dirix L, Lewis KD, Hainsworth JD, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012;366:2171-9.

  34. Chang AL, Solomon JA, Hainsworth JD, Goldberg L, McKenna E, Day BM, et al. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib. J Am Acad Dermatol. 2014;70(1):60-9.

  35. Bello C, Vazquez-Blomquist D, Miranda J, Garcia Y, Novoa LI, Palenzuela D, et al. Regulation by IFN-α/IFN-γ Co-Formulation (HerberPAG®) of Genes Involved in Interferon-STAT-Pathways and Apoptosis in U87MG. Curr Top Med Chem. 2014;14(3):351-8.

  36. Garcia Vega Y, Salva Camaño S, García Iglesias E, Cubero-Rego D, González-Gonzalez J, Bello-Rivero I. CIGB-128, as compassionate intracranial treatment in patients with non-operable or progressive high grade gliomas. J Cancer Res Ther. 2015;3(11):136-43.

  37. Smeets NW, Kuijpers DI, Nelemans P, Ostertag JU, Verhaegh ME, et al. Mohs’ micrographic surgery for treatment of basal cell carcinoma of the face–results of a retrospective study and review of the literature. Br J Dermatol. 2004;151:141-7.

  38. Takamori S, Kong K, Varma S, Leach I, Williams HC, Notingher I. Optimization of multimodal spectral imaging for assessment of resection margins during Mohs micrographic surgery for basal cell carcinoma. Biomed Opt Express. 2015;6:98-111.

  39. Chren MM, Linos E, Torres JS, Stuart SE, Parvataneni R, Boscardin WJ. Tumor recurrence 5 years after treatment of cutaneous basal cell carcinoma and squamous cell carcinoma. J Invest Dermatol. 2013; 133(5):1188-96.




2020     |     www.medigraphic.com